PRX-07034

PRX-07034 is a selective 5-HT₆ receptor antagonist.^[1] It has cognition and memory-enhancing properties and potently decreases food intake and body weight in rodents.^[1][2][3][4] PRX-07034 was under development by Epix Pharmaceuticals for the treatment of obesity and cognitive impairment associated with Alzheimer's disease and schizophrenia but upon the company collapsing due to lack of funds the compound was auctioned to another corporation.^[5][6][7]

PRX-07034

Clinical data
Routes of administration	Oral
ATC code	none
Legal status
Legal status	In general: uncontrolled
Identifiers
IUPAC name N-[1-(5-chloro-2,3-dimethoxyphenyl)ethyl]-2-methylsulfonyl-5-piperazin-1-ylaniline
CAS Number	903580-16-5
PubChem CID	11532574
ChemSpider	9707357
UNII	YJ5TMF911R
CompTox Dashboard (EPA)	DTXSID101116691
Chemical and physical data
Formula	C21H29Cl2N3O4S
Molar mass	490.44 g·mol−1
3D model (JSmol)	Interactive image
SMILES COc2cc(Cl)cc(c2OC)C(C)Nc1cc(ccc1S(=O)(=O)C)N3CCNCC3
InChI InChI=1S/C21H28ClN3O4S/c1-14(17-11-15(22)12-19(28-2)21(17)29-3)24-18-13-16(25-9-7-23-8-10-25)5-6-20(18)30(4,26)27/h5-6,11-14,23-24H,7-10H2,1-4H3 Key:BSLXKMCHXRCBIH-UHFFFAOYSA-N
(verify)